NKTR Related Analyst Ratings
-
MKM Partners Reiterates Bullish Stance on Nektar Therapeutics (NKTR); Phase 3 to Start this Month
-
Lazard Capital Starts Nektar Therapeutics (NKTR) at Buy
-
Jefferies Downgrades Nektar Therapeutics (NKTR) to Hold on Increased Regulatory Risks
-
Deutsche Bank Sees More Upside in Shares of Nektar Therapeutics (NKTR)
-
Needham & Company Downgrades Progenics Pharmaceuticals (PGNX) to Hold; Concerns on Lack of Clarity with Relistor
-
Jefferies Comments on Nektar Therapeutics (NKTR) After Global Healthcare Conference
-
Roth Capital Starts Nektar Therapeutics (NKTR) at Buy
-
UPDATE: Jefferies Starts Nektar Therapeutics (NKTR) at Buy
-
Jefferies Starts Dendreon (DNDN) at Underperform, Nektar (NKTR) at Buy
-
BofA/Merrill Lynch Downgrades Nektar Therapeutics (NKTR) to Underperform
-
ThinkEquity Downgrades Nektar Therapeutics (NKTR) to Sell, Reaffirms $5 Price Target
-
Brean Murray Carret Offers Valuation Break Down on Shares of Nektar Therapeutics (NKTR)
-
Boenning & Scattergood Starts Nektar Therapeutics (NKTR) at Outperform
-
ThinkEquity Downgrades Nektar Therapeutics (NKTR) to Hold
-
Barclays Maintains an 'Equalweight' on Nektar Therapeutics (NKTR); NKTR-102 Not to Be Partnered
-
Cantor Fitzgerald Lowers Price Target on Nektar (NKTR) to $21
-
Cantor Fitzgerald Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; Proven Technology Fuels New Growth
-
Traders Selling Nektar (NKTR) Amid Barclays Downgrade
-
Brean Murray Maintains a 'Buy' on Nektar Therapeutics (NKTR); Raises Price Target
-
Brean Murray Reiterates a 'Buy' on Nektar Therapeutics (NKTR)
-
Wedbush Maintains an 'Outperform' on Nektar Therapeutics (NKTR), Recent Marketing Trip Focused on Upcoming Ovarian Cancer Data
-
Morgan Joseph Reiterates a 'Buy' on Nektar Therapeutics (NKTR)
-
Hapoalim Securities Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; Ongoing Programs to Help Drive Share Price
-
BMO Capital Upgrades Nektar Therapeutics (NKTR) to Outperform
-
Morgan Joseph Reiterates a 'Buy' on Nektar Technology (NKTR); Sees Substantial Added Value From AstraZeneca Deal
-
Wedbush Morgan Maintains an 'Outperform' on Nektar Therapeutics (NKTR); Raises Price Target
-
Boenning & Scattergood Starts Nektar (NKTR) at Outperform
-
Brean Murray Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; Expect Substantial Value Creation Through Partnerships
-
Morgan Joseph Reiterates a 'Buy' on Nektar Therapeutics (NKTR); Partner Momentum Building
-
William Blair & Co Initiates Coverage on Nektar Therapeutics (NKTR) with an Outperform; Near-term Positive Catalysts
-
Morgan Joseph Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; PEG Technology & Pipeline Orchestrating Strong Comeback
-
Matrix USA Rating Changes 9/5
-
Matrix USA Rating Changes 7/25
-
Matrix USA Rating Changes 5/21
-
Matrix USA Rating Changes 5/8
-
Matrix USA Rating Changes 5/6
-
Matrix USA Rating Changes 4/17
-
Matrix USA Rating Changes 4/10
-
Piper Jaffray Downgrades MannKind (MNKD) to Neutral; Slashes PT from $19 to $1.50
-
Pacific Growth Downgrades Nektar Therapeutics (NKTR) to Neutral
-
Merrill Lynch Downgrades Nektar (NKTR) and MannKind (MNKD)
-
Matrix USA Rating Changes 4/2
-
Matrix USA Rating Changes 11/15
-
Matrix USA Rating Changes 11/14
-
Nektar Therapeutics (Nasdaq: NKTR) Bull and Bear Story
-
Nektar Therapeutics (NKTR): Pfizer continues to be serious about Exubera
-
Morgan Stanley upgrades Nektar Therapeutics (NKTR) to Equal Weight
-
WR Hambrecht Said Pfizer (PFE) May Buy Nektar (NKTR) Following Torcetrapib Blow-Up
-
Morgan Stanley downgrades Nektar Therapeutics (NKTR) to Underweight
-
Miller Johnson upgrades Nektar Therapeutics (NKTR) to Outperform
Back to NKTR Stock Lookup
